Group 1 - The core viewpoint of the article highlights the recent performance of Meihao Medical (301363), which closed at 32.86 yuan on February 24, 2026, down by 5.79% with a turnover rate of 4.54% and a trading volume of 169,300 hands, resulting in a transaction amount of 555 million yuan [1] - On February 24, the net outflow of main funds was 40.37 million yuan, accounting for 7.28% of the total transaction amount, while retail investors saw a net inflow of 17.05 million yuan, representing 3.08% of the total transaction amount [1] - The financing data indicates that on the same day, the financing buy amounted to 57.43 million yuan, with a net financing buy of 22.27 million yuan after accounting for repayments [2] Group 2 - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, an increase of 3.28% year-on-year, while the net profit attributable to shareholders decreased by 19.25% to 208 million yuan [3] - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up by 2.56% year-on-year, and a net profit attributable to shareholders of 93.90 million yuan, which is a 5.89% increase year-on-year [3] - The company has a debt ratio of 11.43% and a gross profit margin of 39.34%, indicating a stable financial position within the industry [3]
美好医疗（301363）2月24日主力资金净卖出4036.56万元